Last reviewed · How we verify
Mucomycin (LYMECYCLINE)
Mucomycin (generic name: LYMECYCLINE) is a lymecycline drug. It is currently in Phase 3 development.
Mucomycin works by binding to the bacterial ribosome and inhibiting protein synthesis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LYMECYCLINE |
|---|---|
| Drug class | lymecycline |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Think of it like a factory assembly line. Bacteria need to make proteins to function and grow, and Mucomycin blocks the assembly line by binding to the ribosome, which is the part of the cell where proteins are made. This prevents the bacteria from making the proteins they need to survive and multiply.
Approved indications
Common side effects
- Drug reaction with eosinophilia and systemic symptoms
- Hidradenitis
- Swelling face
- Serum procollagen type III N-terminal propeptide increased
Key clinical trials
- Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients (PHASE3)
- Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients (PHASE3)
- Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris (PHASE3)
- Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced (PHASE4)
- Antiacne Medications Pseudotumor Cerebri (PHASE4)
- Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mucomycin CI brief — competitive landscape report
- Mucomycin updates RSS · CI watch RSS
Frequently asked questions about Mucomycin
What is Mucomycin?
How does Mucomycin work?
What is the generic name of Mucomycin?
What drug class is Mucomycin in?
What development phase is Mucomycin in?
What are the side effects of Mucomycin?
Related
- Drug class: All lymecycline drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing